Radius Health
MA - Boston
BiotechnologyFocus: Small Molecules, Biologics
Radius Health is a life sciences company focused on Small Molecules, Biologics.
EndocrinologyOncology
Funding Stage
PUBLIC
Open Jobs
0
Products & Portfolio (2)
1 discontinued product not shown
BINOSTO
alendronate sodium
Peak
ORAL · TABLET, EFFERVESCENT
action. At the cellular level, alendronate shows preferential localization to sites of bone resorption, specifically under osteoclasts. The osteoclasts adhere normally to the bone surface but lack the ruffled border that is indicative of active resorption. Alendronate does not interfere with osteoclast recruitment or attachment, but it does inhibit osteoclast activity. Studies in mice on the localization of radioactive [H]alendronate in bone showed about 10-fold higher uptake on osteoclast surfaces than on osteoblast surfaces. Bones examined 6 and 49 days after [H]alendronate administration in rats and mice, respectively, showed that normal bone was formed on top of the alendronate, which was incorporated inside the matrix. While incorporated in bone matrix, alendronate is not pharmacologically active. Thus, alendronate must be continuously administered to suppress osteoclasts on newly formed resorption surfaces. Histomorphometry in baboons and rats showed that alendronate treatment reduces bone turnover (i.e., the number of sites at which bone is remodeled). In addition, bone formation exceeds bone resorption at these remodeling sites, leading to progressive gains in bone mass.
osteoporosis in postmenopausal womenosteoporosisalendronate sodium increases bone mass+3 more
2012
0
TYMLOS
abaloparatide
Peak
PeptideSUBCUTANEOUS · SOLUTION
2017
0
Pipeline & Clinical Trials
Abaloparatide
Osteoporosis, PostmenopausalClinical Trials (1)
NCT04974723Real-world Effectiveness and Cardiovascular Safety Study of Abaloparatide in Postmenopausal Women
N/AElacestrant
Breast CancerClinical Trials (1)
NCT04797728Elacestrant in Preoperative Setting, a Window of Opportunity Study
Phase 1abaloparatide-sMTS
Postmenopausal OsteoporosisClinical Trials (1)
NCT04366726Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Usability of Abaloparatide-solid Microstructured Transdermal System (sMTS) in Postmenopausal Women With Low Bone Mineral Density (BMD)
Phase 1abaloparatide-sMTS
OsteoporosisClinical Trials (1)
NCT04936984Study to Evaluate and Compare the Bioequivalence of Two Abaloparatide-sMTS Treatments in Healthy Women.
Phase 1abaloparatide-sMTS
Healthy VolunteersClinical Trials (1)
NCT04663464Study to Evaluate and Compare the PK Profiles of Abaloparatide-SC and Abaloparatide-sMTS in a Cohort of Healthy Men and Healthy Women.
Phase 1Abaloparatide Transdermal
Post Menopausal OsteoporosisClinical Trials (1)
NCT01674621Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis
Phase 2teriparatide
OsteoporosisClinical Trials (1)
NCT00542425Phase 2 Dose-finding Study to Evaluate the Effects of BA058 in the Treatment of Postmenopausal Women With Osteoporosis
Phase 2Alendronate
Postmenopausal OsteoporosisClinical Trials (1)
NCT01657162Twenty-Four Month Extension Study of BA058-05-003 (Abaloparatide) in Participants With Osteoporosis
Phase 3Abaloparatide
Osteoporosis, PostmenopausalClinical Trials (1)
NCT03710889Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption
Phase 3Placebo
OsteoporosisClinical Trials (1)
NCT01343004Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Prevention of Fracture in Postmenopausal Women
Phase 3Abaloparatide
OsteoporosisClinical Trials (1)
NCT03512262Safety and Efficacy of Abaloparatide-SC in Men With Osteoporosis (ATOM)
Phase 3abaloparatide
Postmenopausal OsteoporosisClinical Trials (1)
NCT04064411Efficacy & Safety of Abaloparatide-Solid Microstructured Transdermal System in Postmenopausal Women With Osteoporosis
Phase 3Abaloparatide
Femoral FracturesClinical Trials (1)
NCT04626141Supracondylar Distal Femur Fractures and Abaloparatide
Phase 4Abaloparatide
OsteoporosisClinical Trials (1)
NCT04167163Abaloparatide Before Total Knee Arthroplasty
Phase 4Denosumab Injection
Osteoporosis, PostmenopausalClinical Trials (1)
NCT04467983Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone
Phase 4Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Portfolio: 3 approved products, 15 clinical trials
Top TAs: Endocrinology
Portfolio Health
Peak2 (67%)
Post-LOE1 (33%)
3 total products